American Society of Hematology

SHERPA: Blue

People

  1. Horwitz
    Horwitz
  2. Seshan
    Seshan
  3. Batlevi
    Batlevi
  4. Matasar
    Matasar
  5. Moskowitz
    Moskowitz
  6. Noy
    Noy
  7. Palomba
    Palomba
  8. Younes
    Younes
  9. Zelenetz
    Zelenetz
  10. Hamilton
    Hamilton

Groups

  1. Biostatistics Service (12)
  2. Center for Hematologic Malignancies (12)
  3. Center for Pancreatic Cancer Research (12)
  4. Department of Medicine (12)
  5. Epidemiology and Biostatistics (12)
  6. Hematologic Malignancies, Division of (12)
  7. Lymphoma (12)
  8. Population Sciences Research Program (12)
  9. Executive Committee, Center for Hematologic Malignancies (10)
  10. Sloan Kettering Institute Postdocs (10)
Search Within
  1. "Center for Pancreatic Cancer Research"
  2. "Steven Horwitz"
Formats
  1. Meeting Abstract (9)
  2. Journal Article (3)
Groups
  1. Biostatistics Service (12)
  2. Center for Hematologic Malignancies (12)
  3. Center for Pancreatic Cancer Research (12)
  4. Department of Medicine (12)
  5. Epidemiology and Biostatistics (12)
  6. Hematologic Malignancies, Division of (12)

More Groups

People
  1. Steven Horwitz (12)
  2. Venkatraman Seshan (12)
  3. Alison Moskowitz (10)
  4. Anas Younes (10)
  5. Andrew Zelenetz (10)
  6. Ariela Noy (10)

More People

Years
  1. 2022 (1)
  2. 2021 (2)
  3. 2020 (3)
  4. 2019 (2)
  5. 2017 (1)
  6. 2016 (2)

More Years

Publications
  1. Blood (10)
  2. Blood Advances (2)

Results (12)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
    Journal Article

    Bobillo, S.; Joffe, E.; Lavery, J. A.; Sermer, D.; Ghione, P.; Noy, A.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim analysis from a prospective multicenter study of next-generation sequencing minimal residual disease assessment and CT monitoring for surveillance after frontline treatment in diffuse large B-cell lymphoma
    Meeting Abstract

    Kumar, A.; Westin, J.; Schuster, S. J.; Nowakowski, G. S.; Lossos, I. S.; Batlevi, C. L.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • T follicular helper phenotype prendicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma
    Journal Article

    Ghione, P.; Faruque, P.; Mehta-Shah, N.; Seshan, V.; Ozkaya, N.; Bhaskar, S.; Yeung, J.; Spinner, M. A.; Lunning, M.; Inghirami, G.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma
    Journal Article

    Sermer, D.; Bobillo, S.; Dogan, A.; Zhang, Y.; Seshan, V.; Lavery, J. A.; Batlevi, C.; Caron, P.; Hamilton, A.; Hamlin, P.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Incidence of delayed seromas and related risk of BIA-ALCL in a cohort of 3521 breast cancer women with textured implants prospectively followed long term
    Meeting Abstract

    Ghione, P.; Cordeiro, P.; Seshan, V.; Galasso, N.; Ganesan, N.; Hu, Q.; Dogan, A.; Horwitz, S. M.
    Blood (2019)

    Fulltext@MSK | Save
  • Central nervous system prophylaxis with high-dose intravenous methotrexate or intrathecal chemotherapy in patients with diffuse large B-cell lymphoma and high-risk of CNS relapse treated in the rituximab era
    Meeting Abstract

    Bobillo, S.; Joffe, E.; Seshan, V.; Noy, A.; Horwitz, S. M.; Palomba, M. L.; Matasar, M. J.; Straus, D. J.; Hamlin, P. A.; Batlevi, C. L.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Impact of PET staging of follicular lymphoma on treatment outcomes and prognosis
    Meeting Abstract

    Alperovich, A.; Batlevi, C. L.; Intlekofer, A. M.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, M. L.; Moskowitz, A. J.; Gerecitano, J.; Hamlin, P. A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Outcomes of follicular lymphoma patients by dynamic FLIPI at diagnosis and initial treatment in the post-rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save